![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H17N9 |
Molar mass | 383.419 g·mol−1 |
3D model ( JSmol) | |
| |
|
Ropsacitinib (PF-06826647) is a drug which is an orally active, selective tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various autoimmune inflammatory conditions, primarily plaque psoriasis. [1] [2] [3]
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H17N9 |
Molar mass | 383.419 g·mol−1 |
3D model ( JSmol) | |
| |
|
Ropsacitinib (PF-06826647) is a drug which is an orally active, selective tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various autoimmune inflammatory conditions, primarily plaque psoriasis. [1] [2] [3]